CellaVision s new application for analysis of body fluids pre-launched in the USA

The application will be available for purchase in early 2008.

CellaVision, which develops and sells image analysis based products
for routine analysis of blood, pre-launches a new application for
analysis of body fluids at the international trade convention AACC in
California, USA, between July 15-19. The application is optimized for
analysis of cerebrospinal fluid and targets clinical chemistry
laboratories.

The application for body fluids widens and strengthens CellaVision's
product range for clinical chemistry laboratories. At present, the
application is being evaluated by a number of European laboratories
in order to establish the value of its functionality, capacity, and
user friendliness. The first users are expected to be already
existing users of the company's application for blood and the
analysis instrument CellaVision DM96. Although quantitatively more
blood is analysed, cerebrospinal fluid analysis is of prime
importance to many laboratories.

- This is an important strategic move for us. This application widens
our range of products available to both existing and future clients,
which will have a positive effect on sales, says Yvonne Mårtensson,
CEO of CellaVision.

The advantages of the new application are the same as those for blood
- faster and more standardized results, digital archiving of samples
together with patient records, as well as sharing of digital images
with experts outside the laboratory.
CellaVision will pre-launch the new application alongside
demonstrating the remaining range of products at the international
trade convention AACC Annual Meeting & Clinical Lab Expo in
California, USA, July 15-19. The convention is expecting around 20
000 visitors. At the show, CellaVision will also be represented by
the company's distributor, Sysmex America. For more information about
the convention, visit www.aacc.org.
About CellaVision
CellaVision AB develops, markets, and sells the market leading image
analysis based systems for routine analysis of blood. The company has
a core competence in development of software and hardware for
automatic image analysis of cells and cell changes for applications
in health and medical care. The company develops and markets systems
for automatic differentials of white blood cells and red morphology,
and software for education and quality assurance of differentials.
The company's associates have expertise in advanced imaging analysis,
artificial intelligence, and automated microscopy.

The company headquarters are in Lund, Sweden. The company also has
subsidiaries Jupiter, Fl, USA, and Toronto, ON, Canada. For more
information, visit www.cellavision.com.

CellaVision's share is listed on First North at the OMX Stockholm
Stock Exchange. The company's Certified Advisor is Remium AB.

For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 286 44 00. E-mail: yvonne.martensson@cellavision.com